Skip to content
CompanyNewsHQ

CompanyNewsHQ

CompanyNewsHQ

  • Industry
    • Accountancy
    • Aerospace & Defense
    • Airline
    • Automotive
    • Chemicals
    • Construction
    • Energy
    • Facilities Management
    • Fashion
    • Finance and Utilities
    • Food and Drink
    • Insurance
    • Legal
    • Logistics
    • M&A News
    • Media & Entertainment
    • Medical Device
    • Parcels
    • Pharmaceutical
    • Private Equity
    • Retail
    • Technology
    • Telecoms
    • Travel
  • Companies A-Z
  • Submit A Press Release
  • Subscribe
  • Advertising
  • Market Analysis
  • Contact Us
Pharmaceutical Company News 

PDF

November 25, 2020 Michael Crowe Regeneron Pharmaceuticals

Download PDF


More from: Regeneron Pharmaceuticals | Category: Pharmaceutical Company News
  • ← Xpediator’s 2020 results benefit from diversified, asset-light approach

You May Also Like

Otsuka Announces Top-line Results from Two Phase 3 Studies in Japan for Atopic Dermatitis Drug Candidate Difamilast (OPA-15406)|News Releases | Otsuka Pharmaceutical Co., Ltd.

March 26, 2020 Michael Crowe

GSK announces intention to produce 1 billion doses of pandemic vaccine adjuvant in 2021 to support multiple COVID-19 vaccine collaborations | GSK

May 28, 2020 Michael Crowe

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

May 29, 2020July 9, 2020 Michael Crowe

More Pharmaceutical Company News

  • PDF
  • Lokelma label update approved in China for patients with hyperkalaemia on chronic haemodialysis
  • AbbVie to Present at the Evercore ISI Conference and Piper Sandler Healthcare Conference
  • Announcement of Making Nihon Pharmaceutical Co., Ltd. a Wholly-owned Subsidiary Through Simple Share Exchange
  • Nov 24,2020 | Chugai and DeNA Jointly Launch “Ring Again,” a Rheumatoid Arthritis Disease Awareness Project | News | CHUGAI PHARMACEUTICAL CO., LTD.
  • Roche announces FDA approval of Xofluza for the prevention of influenza following contact with an infected person
  • Meet Novartis Management 2020 | Novartis
  • Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event
  • Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors
  • New hope for treating inflammatory diseases of the kidney | Novartis
  • Amgen To Transition Development And Commercial Rights For Omecamtiv Mecarbil And AMG 594 To Cytokinetics
  • GSK starts phase 3 study of RSV maternal candidate vaccine | GSK
  • AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19
  • European Commission approves MenQuadfi®, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older
  • Regeneron’s REGEN-COV2 is First Antibody Cocktail for COVID-19 to Receive FDA Emergency Use Authorization | Regeneron Pharmaceuticals Inc.
  • Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine
  • Imfinzi approved in the US for less-frequent, fixed-dose use
  • Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
  • Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
  • Predictive analytics could bring medicines to patients faster | Novartis
  • New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases
  • GSK and MMV present positive data on treatment for Plasmodium vivax malaria in children from 6 months up to 15 years of age | GSK
  • Results from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) in Previously Untreated ALK-Positive Lung Cancer Published in the New England Journal of Medicine
  • AstraZeneca demonstrates strengths in haematology with robust data at ASH 2020
  • Nov 19,2020 | Chugai Receives the Best IR Award | News | CHUGAI PHARMACEUTICAL CO., LTD.

About

Company News HQ is a global business news portal. It is the leading industry news source for major companies across a number of industry verticals.

Links

  • Advertising
  • News Tracking Service
  • Submit News
  • Subscribe
  • Contact Us
Copyright © 2020 CompanyNewsHQ. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

  • Industry
    ▼
    • Accountancy
    • Aerospace & Defense
    • Airline
    • Automotive
    • Chemicals
    • Construction
    • Energy
    • Facilities Management
    • Fashion
    • Finance and Utilities
    • Food and Drink
    • Insurance
    • Legal
    • Logistics
    • M&A News
    • Media & Entertainment
    • Medical Device
    • Parcels
    • Pharmaceutical
    • Private Equity
    • Retail
    • Technology
    • Telecoms
    • Travel
  • Companies A-Z
  • Submit A Press Release
  • Subscribe
  • Advertising
  • Market Analysis
  • Contact Us